diabetes skin
Instructed in factors that contribute to poor skin integrity such as immobilization, poor circulation, moisture, heat, anemia, shearing forces, poor nutritional status.
Instructed in new medication Sulfaprim and in S/E such as headache, mental depression, aseptic meningitis, tinnitus, apathy, seizures, hallucinations, ataxia, nervousness, fatigue, vertigo, insomnia, thrombophlebitis, nausea, vomiting, diarrhea, abdominal pain, anorexia, stomatitis, pancreatitis, pseudomembranous colitis, toxic nephrosis with oliguria and anuria, crystalluria, hematuria, interstitial nephritis, agranulocytosis, aplastic anemia, megaloblastic anemia, thrombocytopenia, leukopenia, hemolytic anemia, jaundice, hepatic necrosis, arthralgia, myalgia, muscle weakness, pulmonary infiltrates, erythema multiforme, Stevens-Johnson syndrome, generalized skin eruption, toxic epidermal necrolysis, exfoliative dermatitis, photosensitivity, urticaria, pruritus, hypersensitivity reactions, serum sickness, drug fever and anaphylaxis.
Instructed in new medication Prevacid and in S/E such as headache, dizziness, vertigo, malaise, paresthesia, fever, palpitations, flushing, orbital edema, tinnitus, diarrhea, constipation, anorexia, taste perversion, dry mouth, bone and muscle pain, acne, dry skin and transient irritation at I.V. site.
Instructed in new medication Prednisone and in S/E such as euphoria, insomnia, psychotic behavior, vertigo, headache, paresthesia, seizures, pseudotumor cerebri, heart failure, hypertension, edema, arrhythmias, thrombophlebitis, thromboembolism, cataracts, glaucoma, peptic ulceration, GI irritation, increased appetite, pancreatitis, nausea, vomiting, menstrual irregularities, increased urine calcium levels, hypokalemia, hyperglycemia, carbohydrate intolerance, growth suppression in children, muscle weakness, osteoporosis, hirsutism, delayed wound healing, acne and various skin eruptions.
Instructed in new medication Augmentin to manage infection. In addition, warned of possible S/E such as nausea, vomiting, headache, dizziness, skin rash, blurred vision, confusion, anxiety, redness, etc.
Instructed in S/E of oxygen therapy such as respiratory depression, collapse lung, irritation of airway mucosa, oxygen toxicity, local skin irritation.
Instructed in the use of absorptive products with polymer gel and in change when wet. Wash skin with incontinence wipe or cleanser but avoid excess friction. Avoid soap as it removes natural protective lubricants.
Instructed in new medication Synthroid and in S/E such as nervousness, insomnia, tremor, headache, fever, tachycardia, palpitations, arrhythmias, angina pectoris, cardiac arrest, diarrhea, vomiting, menstrual irregularities, weight loss, allergic skin reactions, diaphoresis or heat intolerance.
Instructed in new medication Bactroban to manage wound care. In addition, warned of possible S/E such as headache, rhinitis, pharyngitis, burning or stinging with intranasal use, taste perversion, upper respiratory tract congestion, cough with intranasal use, burning pruritis, stinging, rash, pain, and erythema with topical use. Instructed to notify prescriber immediately if no improvement occurs in 3 to 5 days or if condition worsens. Advised not to use other nasal products with Bactroban. Warned patient about local adverse reactions related to drug use. Advised not to use cosmetics or other skin products on treated area.
Instructed in signs and symptoms of anemia such as headaches, palpitations, paleness of skin, dizziness, increased sensitivity to cold, brittle fingernails and hair, difficulty swallowing, tiredness, etc.